A decade after its first approval, FDA expands weight loss pill's label for use in adolescents

The FDA late Monday signed off on a supplemental indication for bankrupt Vivus’ Qsymia (phentermine and topiramate) for chronic weight management in obese adolescents aged 12 years and older, defined as those with a body mass index in the 95th percentile or greater.